Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Earnings Results

Tonix Pharmaceuticals (NASDAQ:TNXP) posted its quarterly earnings results on Tuesday. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($2.03) by $1.80, Zacks reports. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 158.64%. The firm had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million.

Tonix Pharmaceuticals Stock Down 2.1 %

TNXP traded down $0.00 during trading on Wednesday, hitting $0.14. 9,519,872 shares of the stock traded hands, compared to its average volume of 10,128,589. Tonix Pharmaceuticals has a 12-month low of $0.12 and a 12-month high of $22.14. The company has a current ratio of 1.15, a quick ratio of 0.72 and a debt-to-equity ratio of 0.13. The firm has a 50-day moving average of $0.15 and a 200 day moving average of $1.50.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on TNXP shares. Alliance Global Partners boosted their price target on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, July 22nd. StockNews.com began coverage on Tonix Pharmaceuticals in a report on Wednesday. They set a “sell” rating for the company.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.